These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 23579273)

  • 1. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma.
    Kocak H; Ackermann S; Hero B; Kahlert Y; Oberthuer A; Juraeva D; Roels F; Theissen J; Westermann F; Deubzer H; Ehemann V; Brors B; Odenthal M; Berthold F; Fischer M
    Cell Death Dis; 2013 Apr; 4(4):e586. PubMed ID: 23579273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
    Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
    Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrin α4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low Neuroblastoma.
    Young SA; McCabe KE; Bartakova A; Delaney J; Pizzo DP; Newbury RO; Varner JA; Schlaepfer DD; Stupack DG
    PLoS One; 2015; 10(5):e0120815. PubMed ID: 25973900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.
    Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells.
    Guglielmi L; Cinnella C; Nardella M; Maresca G; Valentini A; Mercanti D; Felsani A; D'Agnano I
    Cell Death Dis; 2014 Feb; 5(2):e1081. PubMed ID: 24556696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
    Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
    Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma.
    Berwanger B; Hartmann O; Bergmann E; Bernard S; Nielsen D; Krause M; Kartal A; Flynn D; Wiedemeyer R; Schwab M; Schäfer H; Christiansen H; Eilers M
    Cancer Cell; 2002 Nov; 2(5):377-86. PubMed ID: 12450793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
    Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
    Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulated NORAD in neuroblastoma promotes cell proliferation via chromosomal instability and predicts poor prognosis.
    Yu Y; Chen F; Jin Y; Yang Y; Wang S; Zhang J; Chen C; Zeng Q; Han W; Wang H; Guo Y; Ni X
    Acta Biochim Pol; 2020 Dec; 67(4):595-603. PubMed ID: 33326736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Ras expression and caspase-independent neuroblastoma cell death: possible mechanism of spontaneous neuroblastoma regression.
    Kitanaka C; Kato K; Ijiri R; Sakurada K; Tomiyama A; Noguchi K; Nagashima Y; Nakagawara A; Momoi T; Toyoda Y; Kigasawa H; Nishi T; Shirouzu M; Yokoyama S; Tanaka Y; Kuchino Y
    J Natl Cancer Inst; 2002 Mar; 94(5):358-68. PubMed ID: 11880474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
    Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
    J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiling of favorable and unfavorable neuroblastomas.
    Hiyama E; Hiyama K; Yamaoka H; Sueda T; Reynolds CP; Yokoyama T
    Pediatr Surg Int; 2004 Jan; 20(1):33-8. PubMed ID: 14691637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
    Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
    Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.
    Ikram F; Ackermann S; Kahlert Y; Volland R; Roels F; Engesser A; Hertwig F; Kocak H; Hero B; Dreidax D; Henrich KO; Berthold F; Nürnberg P; Westermann F; Fischer M
    Mol Oncol; 2016 Feb; 10(2):344-59. PubMed ID: 26598443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
    Zhong ZY; Shi BJ; Zhou H; Wang WB
    J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
    Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.